{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:11:01Z","timestamp":1793387461515,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine\/z-drugs (BZDRs). Long-term BZDR prescriptions are potentially harmful yet common, partly because of challenging withdrawal symptoms. Few pharmacological interventions have evidence for facilitating BZDR discontinuation, and none in patients actively suffering from TRD. In this ambi-directional cohort study, discontinuation of long-term (&gt;6 month) BZDRs was attempted in 22 patients with severe unipolar or bipolar TRD receiving a course of six subanesthetic ketamine infusions over four weeks. We investigated the rates of successful BZDRs deprescription, trajectories of acute psychological withdrawal symptoms, and subsequent BZDRs abstinence during a mean follow-up of 1 year (primary outcome). Clinically significant deteriorations in depression, anxiety, sleep, and\/or suicidality during the acute BZDR discontinuation phase were measured by repeated standardized scales and analyzed by latent growth curve models and percent correct classification analysis. Of the 22 eligible patients, all enrolled in this study and 91% (20\/22) successfully discontinued all BZDRs by the end of the 4-week intervention, confirmed by urinary analyses. Less than 25% of discontinuers experienced any significant worsening of anxiety, depression, sleep difficulties, or suicidality during treatment. During follow-up (mean [range] duration, 12 [3\u201324] months), 64% (14\/22) of patients remained abstinent from any BZDRs. These preliminary results suggest that ketamine infusions for TRD may facilitate the deprescription of BZDRs, even in patients with active depressive symptoms and significant comorbidity. Further investigation is warranted into this potential novel application of ketamine.<\/jats:p>","DOI":"10.1038\/s41386-023-01689-y","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T16:02:13Z","timestamp":1690992133000},"page":"1769-1777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report"],"prefix":"10.1038","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-9943","authenticated-orcid":false,"given":"Nicolas","family":"Garel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle T.","family":"Greenway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00ea-Anh L.","family":"Dinh-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Thibault-Levesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-508X","authenticated-orcid":false,"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4075-2736","authenticated-orcid":false,"given":"Gustavo","family":"Turecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Rej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Richard-Devantoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"1689_CR1","first-page":"Cd001026","volume":"6","author":"Y Ogawa","year":"2019","unstructured":"Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. 2019;6:Cd001026.","journal-title":"Cochrane Database Syst Rev"},{"key":"1689_CR2","doi-asserted-by":"publisher","first-page":"27767","DOI":"10.4088\/JCP.9058se1c.04gry","volume":"71","author":"JR Davidson","year":"2010","unstructured":"Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin psychiatry. 2010;71:27767.","journal-title":"J Clin psychiatry"},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapsychiatry.2017.1273","volume":"74","author":"GA Bushnell","year":"2017","unstructured":"Bushnell GA, St\u00fcrmer T, Gaynes BN, Pate V, Miller M. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014. JAMA psychiatry. 2017;74:747\u201355.","journal-title":"JAMA psychiatry"},{"key":"1689_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04268-5","volume":"22","author":"S Ahuja","year":"2022","unstructured":"Ahuja S, Brendle M, Smart L, Moore C, Thielking P, Robison R. Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. BMC Psychiatry. 2022;22:634.","journal-title":"BMC Psychiatry"},{"key":"1689_CR5","first-page":"Cd009652","volume":"5","author":"CD Darker","year":"2015","unstructured":"Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015;5:Cd009652.","journal-title":"Cochrane Database Syst Rev"},{"key":"1689_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376:1147\u201357.","journal-title":"N Engl J Med"},{"key":"1689_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ijnp\/pyz007","volume":"22","author":"F Schifano","year":"2019","unstructured":"Schifano F, Chiappini S, Corkery JM, Guirguis A. An insight into Z-drug abuse and dependence: an examination of reports to the European medicines agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol. 2019;22:270\u201377.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","volume":"77","author":"M Lader","year":"2014","unstructured":"Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharm. 2014;77:295\u2013301.","journal-title":"Br J Clin Pharm"},{"key":"1689_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1176\/appi.ajp.2016.16030336","volume":"174","author":"WV McCall","year":"2017","unstructured":"McCall WV, Benca RM, Rosenquist PB, Riley MA, McCloud L, Newman JC, et al. Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA. Am J Psychiatry. 2017;174:18\u201325.","journal-title":"Am J Psychiatry"},{"key":"1689_CR10","first-page":"Cd011481","volume":"3","author":"L Baandrup","year":"2018","unstructured":"Baandrup L, Ebdrup BH, Rasmussen J, Lindschou J, Gluud C, Glenth\u00f8j BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018;3:Cd011481.","journal-title":"Cochrane Database Syst Rev"},{"key":"1689_CR11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","volume":"89","author":"H P\u00e9tursson","year":"1994","unstructured":"P\u00e9tursson H. The benzodiazepine withdrawal syndrome. Addiction 1994;89:1455\u20139.","journal-title":"Addiction"},{"key":"1689_CR12","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s11606-019-05098-0","volume":"34","author":"LB Gerlach","year":"2019","unstructured":"Gerlach LB, Strominger J, Kim HM, Maust DT. Discontinuation of chronic benzodiazepine use among adults in the United States. J Gen Intern Med. 2019;34:1833\u201340.","journal-title":"J Gen Intern Med"},{"key":"1689_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-5198(19)30801-7","volume":"81","author":"M Tsuda","year":"1999","unstructured":"Tsuda M, Shimizu N, Suzuki T. Contribution of glutamate receptors to benzodiazepine withdrawal signs. Jpn J Pharm. 1999;81:1\u20136.","journal-title":"Jpn J Pharm"},{"key":"1689_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0163-7258(03)00029-9","volume":"98","author":"C Allison","year":"2003","unstructured":"Allison C, Pratt J. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Therapeutics. 2003;98:171\u201395.","journal-title":"Pharmacol Therapeutics"},{"key":"1689_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s12640-017-9810-1","volume":"33","author":"S Talarek","year":"2018","unstructured":"Talarek S, Listos J, Orzelska-Gorka J, Serefko A, Kotlinska J. NMDA receptors and NO:cGMP signaling pathway mediate the diazepam-induced sensitization to withdrawal signs in mice. Neurotox Res. 2018;33:422\u201332.","journal-title":"Neurotox Res"},{"key":"1689_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jamapsychiatry.2022.1150","volume":"79","author":"L Peng","year":"2022","unstructured":"Peng L, Meeks TW, Blazes CK. Complex persistent benzodiazepine dependence-when benzodiazepine deprescribing goes awry. JAMA Psychiatry. 2022;79:639\u201340.","journal-title":"JAMA Psychiatry"},{"key":"1689_CR17","doi-asserted-by":"publisher","first-page":"204512532210823","DOI":"10.1177\/20451253221082386","volume":"12","author":"AJ Reid Finlayson","year":"2022","unstructured":"Reid Finlayson AJ, Macoubrie J, Huff C, Foster DE, Martin PR. Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Ther Adv Psychopharmacol. 2022;12:20451253221082386.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1689_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0740-5472(91)90023-4","volume":"8","author":"H Ashton","year":"1991","unstructured":"Ashton H. Protracted withdrawal syndromes from benzodiazepines. J Subst Abus Treat. 1991;8:19\u201328.","journal-title":"J Subst Abus Treat"},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2045125317753340","volume":"8","author":"D Fluyau","year":"2018","unstructured":"Fluyau D, Revadigar N, Manobianco BE. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Therapeutic Adv Psychopharmacol. 2018;8:147\u201368.","journal-title":"Therapeutic Adv Psychopharmacol"},{"key":"1689_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1192\/bjp.178.4.317","volume":"178","author":"FG Zitman","year":"2001","unstructured":"Zitman FG, Couv\u00e9e JE. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry. 2001;178:317\u201324.","journal-title":"Br J Psychiatry"},{"key":"1689_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0165-0327(01)00330-5","volume":"70","author":"JE Couv\u00e9e","year":"2002","unstructured":"Couv\u00e9e JE, Timmermans MA, Zitman FG. The long-term outcome of a benzodiazepine discontinuation programme in depressed outpatients. J Affect Disord. 2002;70:133\u201341.","journal-title":"J Affect Disord"},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178:383\u201399.","journal-title":"Am J Psychiatry"},{"key":"1689_CR23","doi-asserted-by":"crossref","unstructured":"Diekamp B, Borentain S, Fu D-J, Murray R, Heerlein K, Zhang Q, et al. Effect of concomitant benzodiazepine use on efficacy and safety of esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior: pooled randomized, controlled trials. Neuropsychiatric Dis Treatment. 2021;17:2347\u201357.","DOI":"10.2147\/NDT.S314874"},{"key":"1689_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother Psychosom. 2021;90:41\u201348.","journal-title":"Psychother Psychosom"},{"key":"1689_CR25","doi-asserted-by":"publisher","first-page":"109606","DOI":"10.1016\/j.drugalcdep.2022.109606","volume":"239","author":"N Garel","year":"2022","unstructured":"Garel N, McAnulty C, Greenway KT, Lesperance P, Miron JP, Rej S, et al. Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: a systematic review and comprehensive analysis of mechanism of actions. Drug Alcohol Depend. 2022;239:109606.","journal-title":"Drug Alcohol Depend"},{"key":"1689_CR26","doi-asserted-by":"publisher","first-page":"204512532110567","DOI":"10.1177\/20451253211056743","volume":"11","author":"E Whittaker","year":"2021","unstructured":"Whittaker E, Dadabayev AR, Joshi SA, Glue P. Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic Adv Psychopharmacol. 2021;11:20451253211056743.","journal-title":"Therapeutic Adv Psychopharmacol"},{"key":"1689_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jpsychires.2014.07.027","volume":"58","author":"ED Ballard","year":"2014","unstructured":"Ballard ED, Ionescu DF, Voort JLV, Niciu MJ, Richards EM, Luckenbaugh DA, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161\u201366.","journal-title":"J Psychiatr Res"},{"key":"1689_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","volume":"175","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175:150\u201358.","journal-title":"Am J Psychiatry"},{"key":"1689_CR29","doi-asserted-by":"crossref","unstructured":"Duncan WC, Ballard ED, Zarate CA. Ketamine-induced glutamatergic mechanisms of sleep and wakefulness: insights for developing novel treatments for disturbed sleep and mood. Sleep Wake Neurobiol Pharmacol. 2019;253:337\u201358.","DOI":"10.1007\/164_2017_51"},{"key":"1689_CR30","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1689_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1176\/appi.ajp.2021.21050535","volume":"179","author":"JC Markowitz","year":"2022","unstructured":"Markowitz JC, Wright JH, Peeters F, Thase ME, Kocsis JH, Sudak DM. The neglected role of psychotherapy for treatment-resistant depression. Am J Psychiatry. 2022;179:90\u201393.","journal-title":"Am J Psychiatry"},{"key":"1689_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4088\/JCP.13m08852","volume":"76","author":"LB Wan","year":"2015","unstructured":"Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76:247\u201352.","journal-title":"J Clin Psychiatry"},{"key":"1689_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1037\/a0030992","volume":"28","author":"SM Robinson","year":"2014","unstructured":"Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28:154\u201362.","journal-title":"Psychol Addict Behav"},{"key":"1689_CR34","unstructured":"Rush Jr AJ, First MB, Blacker D. Handbook of psychiatric measures. Washington, DC, USA: American Psychiatric Pub; 2009."},{"key":"1689_CR35","first-page":"58","volume":"28","author":"EP Borrelli","year":"2022","unstructured":"Borrelli EP, Bratberg J, Hallowell BD, Greaney ML, Kogut SJ. Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018. J Manag Care Spec Pharm. 2022;28:58\u201368.","journal-title":"J Manag Care Spec Pharm"},{"key":"1689_CR36","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. San Antonio, TX: Psychological Corporation. 1996, 1:10.1037.","DOI":"10.1037\/t00742-000"},{"key":"1689_CR37","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1590\/1516-4446-2012-1048","volume":"35","author":"Y-P Wang","year":"2013","unstructured":"Wang Y-P, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Braz J Psychiatry. 2013;35:416\u201331.","journal-title":"Braz J Psychiatry"},{"key":"1689_CR38","unstructured":"Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the state-trait anxiety inventory. Palo Alto, CA, USA: Consulting Psychologists Press; 1983."},{"key":"1689_CR39","doi-asserted-by":"crossref","unstructured":"Spielberger CD. State-trait anxiety inventory: a comprehensive bibliography. Consulting Psychologists Press; 1984.","DOI":"10.1037\/t06496-000"},{"key":"1689_CR40","doi-asserted-by":"crossref","unstructured":"Shahid A, Wilkinson K, Marcu S, Shapiro CM. Leeds sleep evaluation questionnaire (LSEQ). In: STOP, THAT and one hundred other sleep scales. New York, NY, USA: Springer Science & Business Media; 2012, p. 211\u201313.","DOI":"10.1007\/978-1-4419-9893-4_48"},{"key":"1689_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.455","volume":"18","author":"N Zisapel","year":"2003","unstructured":"Zisapel N, Laudon M. Subjective assessment of the effects of CNS\u2010active drugs on sleep by the Leeds sleep evaluation questionnaire: a review. Hum Psychopharmacol. 2003;18:1\u201320.","journal-title":"Hum Psychopharmacol"},{"key":"1689_CR42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/hup.534","volume":"18","author":"R Tarrasch","year":"2003","unstructured":"Tarrasch R, Laudon M, Zisapel N. Cross\u2010cultural validation of the Leeds sleep evaluation questionnaire (LSEQ) in insomnia patients. Hum Psychopharmacol. 2003;18:603\u201310.","journal-title":"Hum Psychopharmacol"},{"key":"1689_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1037\/0022-006X.47.2.343","volume":"47","author":"AT Beck","year":"1979","unstructured":"Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47:343\u201352.","journal-title":"J Consult Clin Psychol"},{"key":"1689_CR44","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.psychres.2014.11.075","volume":"225","author":"DP de Beurs","year":"2015","unstructured":"de Beurs DP, Fokkema M, de Groot MH, de Keijser J, Kerkhof AJ. Longitudinal measurement invariance of the Beck Scale for Suicide Ideation. Psychiatry Res. 2015;225:368\u201373.","journal-title":"Psychiatry Res"},{"key":"1689_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1037\/h0081254","volume":"14","author":"P Bourque","year":"1982","unstructured":"Bourque P, Beaudette D. \u00c9tude psychometrique du questionnaire de d\u00e9pression de Beck aupr\u00e8s d'un \u00e9chantillon d'\u00e9tudiants universitaires francophones. Can J Behav Sci. 1982;14:211.","journal-title":"Can J Behav Sci"},{"key":"1689_CR46","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1037\/h0078881","volume":"25","author":"J Gauthier","year":"1993","unstructured":"Gauthier J, Bouchard S. Adaptation canadienne-fran\u00e7aise de la forme r\u00e9vis\u00e9e du State\u2013Trait Anxiety Inventory de Spielberger. Can J Behav Sci. 1993;25:559.","journal-title":"Can J Behav Sci"},{"key":"1689_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1037\/h0079870","volume":"19","author":"AF de Man","year":"1987","unstructured":"de Man AF, Balkou ST, Iglesias R. A French-Canadian adaptation of the Scale for Suicide Ideation. Can J Behav Sci. 1987;19:50.","journal-title":"Can J Behav Sci"},{"key":"1689_CR48","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3758\/s13428-017-0976-5","volume":"50","author":"D McNeish","year":"2018","unstructured":"McNeish D, Matta T. Differentiating between mixed-effects and latent-curve approaches to growth modeling. Behav Res Methods. 2018;50:1398\u2013414.","journal-title":"Behav Res Methods"},{"key":"1689_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1\u201348.","journal-title":"J Stat Softw"},{"key":"1689_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v082.i13","volume":"82","author":"A Kuznetsova","year":"2017","unstructured":"Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82:1\u201326.","journal-title":"J Stat Softw"},{"key":"1689_CR51","doi-asserted-by":"crossref","unstructured":"Bollen KA, Curran PJ. Latent curve models: a structural equation approach. Wiley Intersciences: Hoboken, NJ; 2006.","DOI":"10.1002\/0471746096"},{"key":"1689_CR52","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/2515245920922982","volume":"3","author":"JW Grice","year":"2020","unstructured":"Grice JW, Medellin E, Jones I, Horvath S, McDaniel H, O\u2019lansen C, et al. Persons as effect sizes. Adv Methods Pract Psychological Sci. 2020;3:443\u201355.","journal-title":"Adv Methods Pract Psychological Sci"},{"key":"1689_CR53","unstructured":"Morley S, Dowzer C. The leeds reliable change indicator. Leeds, UK: University of Leeds; 2014."},{"key":"1689_CR54","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","volume":"67","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Ball R, Ranieri W. Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67:588\u201397.","journal-title":"J Pers Assess"},{"key":"1689_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12955-018-0876-0","volume":"16","author":"MD Manzar","year":"2018","unstructured":"Manzar MD, Salahuddin M, Maru TT, Alghadir A, Anwer S, Bahammam AS, et al. Validation of the adapted Leeds sleep evaluation questionnaire in Ethiopian university students. Health Qual Life Outcomes. 2018;16:49.","journal-title":"Health Qual Life Outcomes"},{"key":"1689_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1037\/0022-006X.59.1.12","volume":"59","author":"NS Jacobson","year":"1991","unstructured":"Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12\u20139.","journal-title":"J Consult Clin Psychol"},{"key":"1689_CR57","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1001\/archpsyc.1990.01810220024003","volume":"47","author":"E Schweizer","year":"1990","unstructured":"Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47:908\u201315.","journal-title":"Arch Gen Psychiatry"},{"key":"1689_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-020-02935-z","volume":"20","author":"S-S Huang","year":"2020","unstructured":"Huang S-S, Chen H-H, Wang J, Chen WJ, Chen H-C, Kuo P-H. Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study. BMC Psychiatry. 2020;20:1\u201312.","journal-title":"BMC Psychiatry"},{"key":"1689_CR59","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/add.14596","volume":"114","author":"P Brenner","year":"2019","unstructured":"Brenner P, Brandt L, Li G, DiBernardo A, Bod\u00e9n R, Reutfors J. Treatment\u2010resistant depression as risk factor for substance use disorders\u2014a nation\u2010wide register\u2010based cohort study. Addiction. 2019;114:1274\u201382.","journal-title":"Addiction."},{"key":"1689_CR60","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/NMD.0000000000000348","volume":"203","author":"GB Parker","year":"2015","unstructured":"Parker GB, Graham RK. Determinants of treatment-resistant depression: the salience of benzodiazepines. J Nerv Ment Dis. 2015;203:659\u201363.","journal-title":"J Nerv Ment Dis"},{"key":"1689_CR61","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jpsychires.2019.06.015","volume":"116","author":"WV McCall","year":"2019","unstructured":"McCall WV, Benca RM, Rumble ME, Case D, Rosenquist PB, Krystal AD. Prevalence of obstructive sleep apnea in suicidal patients with major depressive disorder. J Psychiatr Res. 2019;116:147\u201350.","journal-title":"J Psychiatr Res"},{"key":"1689_CR62","doi-asserted-by":"publisher","first-page":"9720","DOI":"10.3390\/ijerph18189720","volume":"18","author":"T-W Hsu","year":"2021","unstructured":"Hsu T-W, Chen H-M, Chen T-Y, Chu C-S, Pan C-C. The association between use of benzodiazepine receptor agonists and the risk of obstructive sleep apnea: a nationwide population-based nested case-control study. Int J Environ Res Public Health. 2021;18:9720.","journal-title":"Int J Environ Res Public Health"},{"key":"1689_CR63","doi-asserted-by":"crossref","unstructured":"Rao D, Xu G, Lu Z, Liang H, Lin K, Tang M. Comparative study of cognitive function between treatment-resistant depressive patients and first-episode depressive patients. Neuropsychiatric Disease and Treatment. 2019;15:3411\u201317.","DOI":"10.2147\/NDT.S226405"},{"key":"1689_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","volume":"18","author":"MJ Barker","year":"2004","unstructured":"Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18:37\u201348.","journal-title":"CNS Drugs"},{"key":"1689_CR65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0006-8993(98)00052-3","volume":"790","author":"M Tsuda","year":"1998","unstructured":"Tsuda M, Suzuki T, Misawa M. NMDA receptor antagonists potently suppress the spontaneous withdrawal signs induced by discontinuation of long-term diazepam treatment in Fischer 344 rats. Brain Res. 1998;790:82\u201390.","journal-title":"Brain Res"},{"key":"1689_CR66","first-page":"e20114","volume":"13","author":"K Purcell","year":"2021","unstructured":"Purcell K, Bianchi PW, Glenn D, Blakey B, Motov S. Ketamine: a potential adjunct for severe benzodiazepine withdrawal. Cureus. 2021;13:e20114.","journal-title":"Cureus."}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01689-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T18:05:00Z","timestamp":1697479500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01689-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1038\/s41386-023-01689-y","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SR, DJ-A and GT hold research scholar awards from the Fonds de Recherche du Qu\u00e9bec en Sant\u00e9. DJ-A receives study materials from Tetra Bio Pharma for a clinical trial funded by the Quebec Ministry\u00a0of Health and Social Services which is not related to the topic of the present manuscript. No other disclosures were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}